Gilead, Sanofi Ink Academic R&D Pacts | April 4, 2011 Issue - Vol. 89 Issue 14 | Chemical & Engineering News
Volume 89 Issue 14 | p. 17 | Concentrates
Issue Date: April 4, 2011

Gilead, Sanofi Ink Academic R&D Pacts

Department: Business
Keywords: academic research collaboration, cancer, diabetes

Gilead Sciences and Yale School of Medicine have formed a multiyear collaboration to discover novel cancer therapies. Research will focus on the genetic basis and underlying mechanisms of cancer. Gilead will fund the initial four-year research period with up to $40 million and could pay as much as $100 million over 10 years if the project is renewed. Meanwhile, Sanofi-Aventis has formed a collaboration with Columbia University Medical Center focused on diabetes treatments. The three-year project will investigate the role of osteocalcin, an osteoblast-secreted peptide, in diabetes management. Sanofi will fund research at Columbia and will have an option to license existing patents and results from ongoing research.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment